Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $10.00.

A number of research analysts recently issued reports on the company. Oppenheimer restated an "outperform" rating and set a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reaffirmed a "neutral" rating and issued a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th.

Ventyx Biosciences Stock Up 5.3 %

VTYX traded up $0.12 on Tuesday, reaching $2.37. The company had a trading volume of 1,123,580 shares, compared to its average volume of 2,041,259. The stock has a 50-day moving average price of $2.29 and a 200-day moving average price of $2.42. The stock has a market capitalization of $167.58 million, a PE ratio of -1.00 and a beta of 0.48. Ventyx Biosciences has a 1 year low of $1.67 and a 1 year high of $11.48.

Insider Buying and Selling at Ventyx Biosciences

In other Ventyx Biosciences news, CEO Raju Mohan bought 261,752 shares of the business's stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $2.01 per share, with a total value of $526,121.52. Following the purchase, the chief executive officer now owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 18.18% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in Ventyx Biosciences by 273.1% in the 3rd quarter. Barclays PLC now owns 80,295 shares of the company's stock worth $175,000 after acquiring an additional 58,776 shares during the period. Geode Capital Management LLC grew its position in Ventyx Biosciences by 5.9% during the third quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company's stock valued at $3,034,000 after acquiring an additional 77,350 shares during the period. XTX Topco Ltd purchased a new stake in Ventyx Biosciences during the third quarter valued at about $246,000. State Street Corp increased its stake in Ventyx Biosciences by 0.8% during the third quarter. State Street Corp now owns 1,187,650 shares of the company's stock worth $2,589,000 after acquiring an additional 9,783 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Ventyx Biosciences by 19.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 568,479 shares of the company's stock worth $1,239,000 after purchasing an additional 92,753 shares during the period. 97.88% of the stock is currently owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.